TRPV2 and breast carcinoma: In breast cancer cell line MCF-7, Trinilast blocks IGF-1-induced low TRPV2 expression by inhibiting voltage-independent Ca2+ channel-mediated calcium in-flow (Chakrabarti et al., 2009).